Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more

Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. We have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. Here, we discuss the implications of these fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Turnis, Meghan E., Korman, Alan J., Drake, Charles G., Vignali, Dario A.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494635/
https://www.ncbi.nlm.nih.gov/pubmed/23170269
http://dx.doi.org/10.4161/onci.20593
_version_ 1782249419794546688
author Turnis, Meghan E.
Korman, Alan J.
Drake, Charles G.
Vignali, Dario A.A.
author_facet Turnis, Meghan E.
Korman, Alan J.
Drake, Charles G.
Vignali, Dario A.A.
author_sort Turnis, Meghan E.
collection PubMed
description Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. We have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. Here, we discuss the implications of these findings in the context of future combinatorial immunotherapeutic approaches.
format Online
Article
Text
id pubmed-3494635
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946352012-11-20 Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more Turnis, Meghan E. Korman, Alan J. Drake, Charles G. Vignali, Dario A.A. Oncoimmunology Author's View Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. We have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. Here, we discuss the implications of these findings in the context of future combinatorial immunotherapeutic approaches. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494635/ /pubmed/23170269 http://dx.doi.org/10.4161/onci.20593 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Turnis, Meghan E.
Korman, Alan J.
Drake, Charles G.
Vignali, Dario A.A.
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title_full Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title_fullStr Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title_full_unstemmed Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title_short Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
title_sort combinatorial immunotherapy: pd-1 may not be lag-ing behind any more
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494635/
https://www.ncbi.nlm.nih.gov/pubmed/23170269
http://dx.doi.org/10.4161/onci.20593
work_keys_str_mv AT turnismeghane combinatorialimmunotherapypd1maynotbelagingbehindanymore
AT kormanalanj combinatorialimmunotherapypd1maynotbelagingbehindanymore
AT drakecharlesg combinatorialimmunotherapypd1maynotbelagingbehindanymore
AT vignalidarioaa combinatorialimmunotherapypd1maynotbelagingbehindanymore

Ejemplares similares